UBE2I recombinant protein

Recombinant Human UBE2I Protein

Cat. Num. AAA2545375

• Gene Names: UBE2I; P18; UBC9; C358B7.1
• Purity: > 90 % as determined by SDS-PAGE
• Synonyms: UBE2I; Recombinant Human UBE2I Protein; C358B7.1; P18; UBC9; UBE2I recombinant protein

• Host: E Coli
• Purity/Purification: > 90 % as determined by SDS-PAGE
• Form/Format: Lyophilized from sterile PBS, 10% glycerol, 2mM DTT, pH 7.4
• Sequence Length: 158

• Application Notes: The recombinant human UBE2I consists of 160 amino acids and migrates as an approximately 18 kDa band in SDS-PAGE under reducing conditions as predicted.
• Predicted N Terminal: Gly
• Preparation and Storage: Samples are stable for up to twelve months from date of receipt at -70 degree C

SDS-PAGE

Related Product Information for UBE2I recombinant protein

Background: UBE2I is a member of the ubiquitin-conjugating E2 family whose members perform the second step in the ubiquitination reaction. Initially identified as the main process for protein degradation, ubiquitination is believed nowadays to be crucial for a wider range of cellular processes. The outcome of the ubiquitin-conjugation reaction, and thereby the fate of the substrate, is heavily dependent on the number of ubiquitin molecules attached and how these ubiquitin molecules are inter-connected. To deal with this complexity and to allow adequate ubiquitination in time and space, a highly sophisticated conjugation machinery has been developed. In a sequential manner, ubiquitin becomes activated by an ubiquitin-activating enzyme (E1), which then transfers the ubiquitin to a group of ubiquitin-conjugating enzymes (E2s). Next, ubiquitin-loaded E2s are interacting with ubiquitin protein ligases (E3s) and ubiquitin is conjugated to substrates on recruitment by the E3. These three key enzymes are operating in a hierarchical system, wherein two E1s and 35 E2s have been found and hundreds of E3s have been identified in humans. 

Description: A DNA sequence encoding the human UBE2I (P63279) (Met 1-Ser 158) was expressed and purified, with additional two amino acids (Gly & Pro) at the N-terminus.

NCBI and Uniprot Product Information

• NCBI GI #: 4507785
• NCBI GeneID: 7329
• NCBI Accession #: NP_003336.1
• NCBI GenBank Nucleotide #: NM_003345.4
• UniProt Accession #: P63279; P50550; Q15698; Q59GX1; Q86VB3; D3DU69
• Molecular Weight: 18,007 Da
• NCBI Official Full Name: SUMO-conjugating enzyme UBC9
• NCBI Official Synonym Full Names: ubiquitin conjugating enzyme E2 I
• NCBI Official Symbol: UBE2I
• NCBI Official Synonym Symbols: P18; UBC9; C358B7.1
• NCBI Protein Information: SUMO-conjugating enzyme UBC9
• UniProt Protein Name: SUMO-conjugating enzyme UBC9
• UniProt Gene Name: UBE2I
• UniProt Synonym Gene Names: UBC9; UBCE9

NCBI Description

The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: ubiquitin-activating enzymes, or E1s, ubiquitin-conjugating enzymes, or E2s, and ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. Four alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Jul 2008]

Uniprot Description

UBC9: Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3 and SUMO4 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2 or CBX4. Can catalyze the formation of poly- SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Interacts with HIPK1, HIPK2, PPM1J, RASD2 and TCF3 Interacts with NR2C1; the interaction promotes its sumoylation. Forms a tight complex with RANGAP1 and RANBP2. Interacts with SIAH1 and PARP. Interacts with various transcription factors such as TFAP2A, TFAP2B, TFAP2C, AR, ETS1 and SOX4. Interacts with RWDD3; the interaction enhances the sumoylation of a number of proteins such as HIF1A and I-kappa-B. Interacts with DNMT1. Interacts with FOXL2. Forms a complex with SENP6 and UBE2I in response to UV irradiation. Interacts with human herpesvirus 6 IE2. Interacts with human adenovirus early E1A protein; this interaction interferes with polysumoylation (Probable). Interacts with DNM1l (via its GTPase and B domains); the interaction promotes sumoylation of DNM1L, mainly in its B domain. Interacts with PML-RARA oncoprotein (via the coiled-colied domain); the interaction is required for sumoylation of the PML- RARA oncoprotein. Interacts with IPO13. Interacts with NFATC2IP; this inhibits formation of poly-SUMO chains. Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus. Belongs to the ubiquitin-conjugating enzyme family.

Protein type: EC 6.3.2.-; EC 6.3.2.19; Ligase; Nuclear receptor co-regulator; SUMO conjugating system; Ubiquitin conjugating system; Ubiquitin ligase

Chromosomal Location of Human Ortholog: 16p13.3

Cellular Component: cytoplasm; cytosol; nuclear envelope; nucleoplasm; nucleus; PML body; synaptonemal complex

Molecular Function: enzyme binding; protein binding; SUMO ligase activity; transcription factor binding; ubiquitin protein ligase binding

Biological Process: negative regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; protein modification process; protein sumoylation; ubiquitin-dependent protein catabolic process